

Special Issue

Nanotechnology for the Prevention, Diagnosis, and Therapy of HIV, HCV, and Coinfection: From Bench to Bedside

Message from the Guest Editors

HIV and HCV continue to be major global health challenges, affecting millions worldwide. While antiretroviral therapy (ART) and direct-acting antivirals (DAAs) have revolutionized treatment outcomes, persistent issues (including drug resistance, toxicity, poor adherence, and lack of a rapid diagnostic tool) still hamper effective disease control. Nanotechnology offers innovative solutions across the continuum of care from prevention and early detection to therapeutic intervention. This Special Issue invites original research articles, reviews, and perspectives on nanotechnology-enabled strategies for HIV, HCV, and HIV/HCV coinfection. Topics of interest include, but are not limited to:

- Design and engineering of multifunctional nanocarriers for prevention, diagnosis, and therapy
- Long-acting and controlled-release nanomedicines for antiviral delivery
- Integration of diagnostic and therapeutic functionalities in nanoplatforms
- Nanomaterials for vaccine formulation and delivery
- Biopharmaceutical and pharmacokinetic characterization of nano-enabled systems
- Translation from laboratory research to clinical applications in HIV and HCV management

Guest Editors

Dr. Daniel Sepúlveda-Crespo

Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), 28220 Madrid, Spain

Dr. Salvador Resino

Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Madrid, Spain

Deadline for manuscript submissions

31 December 2026



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/251280

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).